Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7344
Source ID: NCT01780051
Associated Drug: Repaglinide/Metformin Combination, Repaglinide, Metformin
Title: A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Repaglinide/Metformin combination, Repaglinide, Metformin|DRUG: Repaglinide/Metformin combination, Repaglinide, Metformin
Outcome Measures: Primary: AUCt and Cmax of repaglinide and metformin, Before study drug administration(0h) and after 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h of study drug administration. | Secondary: AUC∞, Tmax, t1/2, CL/F and Vd/F of repaglinide and metformin, Before study drug administration(0h) and after 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h of study drug administration.
Sponsor/Collaborators: Sponsor: Dalim BioTech Co., Ltd.
Gender: MALE
Age: ADULT
Phases: PHASE1
Enrollment: 48
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2013-03
Completion Date: 2013-04
Results First Posted:
Last Update Posted: 2013-05-15
Locations: Chounbuk National University Hospital, Jeonju, Jeonbuk, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT01780051